HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Tommaso Claudio Mineo Vincenzo Ambrogi Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mineo, T. C. Articles by Roselli, M. Search for Related Content PubMed PubMed Citation Articles by Mineo, T. C. Articles by Roselli, M. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2001;20:378-384
© 2001 Elsevier Science NL

Postoperative adjuvant therapy for stage IB non-small-cell lung cancer

Department of Thoracic Surgery, Tor Vergata University, Rome, Italy

Received 21 November 2000; received in revised form 27 March 2001; accepted 1 May 2001.

Corresponding author. Tel.: +39-06-51002594; fax: +39-06-5922681
e-mail: mineo{at}med.uniroma2.it

Objective: Although surgical resection alone is considered adequate treatment in stage IB non-small-cell lung cancer (NSCLC), long-term survival is not satisfactory and the recurrence rate is quite high. The validity of postoperative chemotherapy at stage IB in terms of disease-free and overall survival was assessed in a randomised trial. Methods: The trial was designed as a randomised, two-group study with postoperative adjuvant chemotherapy versus surgery alone as control group. All patients had stage IB disease (pT2N0) assessed after a radical surgical procedure. Chemotherapy consisted of treatment with cisplatin (100 mg/m² on day 1) and etoposide (120 mg/m² on days 1–3) for a total of six cycles. Results: Between January 1988 and December 1994, 66 patients were included in the study. Thirty-three belonged to the adjuvant chemotherapy group and 33 to the control group. Groups were homogeneous for conventional risk factors. There was no clinical significant morbidity associated to chemotherapy. Patients were followed for a minimum period of 5 years. The rates of locoregional recurrence and distant metastases were 18 and 30%, respectively, in the adjuvant chemotherapy group and 24 and 43%, respectively, in the control group. The 5-year disease-free survival rates were 59% in the adjuvant group and 30% in the control group (P=0.02). The difference in the Kaplan–Meier survival between the groups was significant as assessed using the log-rank test (P=0.04). Conclusions: Our results suggest that adjuvant chemotherapy may reduce recurrences and prolong overall survival in patients at stage IB NSCLC deemed radically operated. Despite being difficult to accept, the use of adjuvant chemotherapy might have better long-term results.

Key Words: Thoracic surgery • Non-small-cell lung cancer • Adjuvant chemotherapy

This article has been cited by other articles:

				K. M.W. Pisters, W. K. Evans, C. G. Azzoli, M. G. Kris, C. A. Smith, C. E. Desch, M. R. Somerfield, M. C. Brouwers, G. Darling, P. M. Ellis, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non Small-Cell Lung Cancer Guideline J. Clin. Oncol., December 1, 2007; 25(34): 5506 - 5518. [Abstract] [Full Text] [PDF]

				J. R. Molina, A. A. Adjei, and J. R. Jett Advances in Chemotherapy of Non-small Cell Lung Cancer. Chest, October 1, 2006; 130(4): 1211 - 1219. [Abstract] [Full Text] [PDF]

				N. Alam, G. Darling, F. A. Shepherd, J. A. Mackay, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta Postoperative Chemotherapy in Nonsmall Cell Lung Cancer: A Systematic Review. Ann. Thorac. Surg., May 1, 2006; 81(5): 1926 - 1936. [Abstract] [Full Text] [PDF]

				A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer Chest, October 1, 2005; 128(4): 2933 - 2943. [Abstract] [Full Text] [PDF]

				J. H. Park, C.-T. Lee, H. W. Lee, H. J. Baek, J. I. Zo, and Y. M. Shim Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1086 - 1091. [Abstract] [Full Text] [PDF]

				K. M.W. Pisters and T. Le Chevalier Adjuvant Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3270 - 3278. [Abstract] [Full Text] [PDF]

				K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-Analysis of Randomized Controlled Trials J. Clin. Oncol., October 1, 2004; 22(19): 3860 - 3867. [Abstract] [Full Text] [PDF]

				A. Sedrakyan, J. van Der Meulen, K. O'Byrne, J. Prendiville, J. Hill, and T. Treasure Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 414 - 419. [Abstract] [Full Text] [PDF]

				K. Yamamoto, J. Padilla Alarcon, V. Calvo Medina, A. Garcia-Zarza, J. Pastor Guillen, E. Blasco Armengod, and F. Paris Romeu Surgical results of stage I non-small cell lung cancer: comparison between elderly and younger patients Eur. J. Cardiothorac. Surg., January 1, 2003; 23(1): 21 - 25. [Abstract] [Full Text] [PDF]

				O. Rena, A. Oliaro, A. Cavallo, P. L. Filosso, G. Donati, P. Di Marzio, G. Maggi, and E. Ruffini Stage I non-small cell lung carcinoma: really an early stage? Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 514 - 519. [Abstract] [Full Text] [PDF]